U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07064720) titled 'Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure' on July 06.
Brief Summary: Dexmedetomidine is a potent alpha-2 adrenergic receptor agonist. In addition, dexmedetomidine-induced stimulation of the postsynaptic alpha-2 adrenergic receptor on the cerebral blood vessels can cause cerebral vasoconstriction and decrease cerebral blood flow
Study Start Date: April 12, 2024
Study Type: INTERVENTIONAL
Condition:
Dexmedetomidine
Intervention:
DRUG: Dexmedetomidine with Mannitol
receive 1 mcg/kg of dexmedetomidine added to 0.4 mcg/kg of mannitol
DRUG: Mannitol (20%)
receive 0.5 g/kg of mannitol
...